Vividion launches with $50M series A round

Vividion Therapeutics Inc. debuted on Thursday with a $50 million series A round. The company's target identification and drug development platform is designed to create candidates against proteins that have previously been considered undruggable.

New investors Arch Venture Partners and Versant Ventures co-led the round and were joined by existing investor Cardinal Partners. Versant's Tom Woiwode declined to say whether the round was tranched. He said it is enough to "advance a couple of programs."...